1. Introduction {#s0005}
===============

Persistent infection with an oncogenic HPV type is the causative agent of cervical cancer ([@bb0115]; [@bb0020]). Multiple sexual partners and young age at sexarche are factors associated with increased exposure risks ([@bb0020]; [@bb0025]). Studies reported that sex workers have more than twice probability of having HPV infection and also a higher prevalence of abnormal Pap smears than non sex workers, in the general population ([@bb0110]; [@bb0075]). Globally, there are few studies published with statistical data on HPV and cancer in FSW ([@bb0100]; [@bb0060]; [@bb0035]; [@bb0085]; [@bb0030]).

In the Caribbean region prostitution is common and the region is on the list of regions well known for sex tourism ([@bb0080]; [@bb0095]; [@bb0040]; [@bb0005]). Cervical cancer is the 2nd most common cancer among women in Latin America and the Caribbean ([@bb0070]; [@bb0050]). For the year 2030, the incidence and mortality are projected to increase by 45% and 60%, if no action is taken ([@bb0050]). Low income- and developing-countries attribute with 85% of annual cervical cancer incidence ([@bb0050]). To be more specific, while the incidence and mortality of cervical cancer attribute to 12% of the cancer cases in Latin America and the Caribbean, statistics show 2% for both incidence and mortality in North America ([@bb0050]). In regions with a lower gross domestic product (GDP) per capita, women are at greater risk for developing cervical cancer, and they also have a greater risk of dying from this disease ([@bb0050]).

On Curaçao, legal prostitution was established since 1949 with only one licensed brothel on the island. It has the capacity for 120 female sex workers (FSW), the number of clients per sex worker per 3 months is approximately 600 clients. Only women from abroad work at the brothel. After 3 months the work and residence license of the FSW expires, and she moves back to her country of birth or she hops between Caribbean islands or Latin American countries. All FSW are medically examined for sexual transmitted diseases (STDs) when they start working at the brothel and receive medical check-up every two weeks thereafter. (Mr. M. Regales, Manager at the brothel, personal communication).

The Caribbean including Curaçao is known for its high HPV prevalence ([@bb0070]; [@bb0050]; [@bb0055]). When considering implementation of preventive strategies in high risk groups including FSW in Curaçao, the prevalence of HPV and HPV genotypes should also be taken into account besides social and behaviour aspects.

Previously we have shown that the proportion of HPV16 and 18 associated cervical cancer is lower and consequently the attribution of the HPV genotypes 31, 45, 51, 52 and 58 is higher compared to world population ([@bb0065]). Also differences in HPV genotype prevalence in cervical cancer between the different islands exist ([@bb0065] PLoS submitted. "Human papillomavirus (HPV) prevalence and associated risk factors in women from Curaçao". Under review).

In this study we set out to identify HPV genotype prevalence and HPV associated risk factors in FSWs compared to age matched women not working in the sex industry.

2. Material and methods {#s0010}
=======================

2.1. Study design and study population {#s0015}
--------------------------------------

In December 2014, seventy-six FSW from Colombia and the Dominican Republic, voluntarily participated in this study and they constitute about 60% of the sex workers working at the brothel in Curaçao. Two hundred and twenty eight age-matched control women (referred to as non FSW, or NFSW) were obtained from women of two trials we conducted on HPV prevalence among the general female population of Curaçao. The first pilot trial was conducted in October 2014, and consists of 253 sexually active women from the general population who volunteered to participate. The second trial was conducted between March-June 2015. In this trial, 1075 women, at random selected from the general population and equally stratified in four age groups from 25 to 65 years were included. (Hooi et al. PLoS submitted.) For the present study, all FSWs were age matched with controls from the general population trials (ratio 1:3, age ± 3 y), taken from the two HPV prevalence studies.

All participants provided a written informed consent and answered a questionnaire on their gynaecological medical history and sexual behaviour.

Ethical approval of the study was obtained from the Institutional review board of the medical ethics committee of Fundashon Prevenshon, Curaçao (IRB board\'s approval number 2015/0004).

2.2. Data collection {#s0020}
--------------------

The survey was carried out by a registered nurse. Personal data and information about gynaecological medical history such as history of abnormal Pap results, sexual transmitted disease (STD) and sexual behaviour such as age of sex-arche and number of lifetime sexual partners were obtained.

2.3. Specimen collection and handling {#s0025}
-------------------------------------

After completion of the anonymous questionnaire, cervical scrapes were collected with a cervical brush by a medical doctor for HPV analyses. Scrapes were conserved in phosphate buffered saline (PBS) for FSW and the Remmel® transport medium for NFSW. At the end of the day all samples were stored at −20 °C.

2.4. HPV detection and genotyping by means of GP5+/6+ amplimer with the Enzyme immune assay (EIA kit HPV GP HR) {#s0030}
---------------------------------------------------------------------------------------------------------------

The MagnaPure 96 instrument was used for DNA isolation. Ten μL of extracted DNA was used as input for the broad spectrum GP5+/6+-PCR in a total volume of 50 μL. Detection of hrHPV was done on 5 μL GP5+/6+ amplimer with the Enzyme immune assay (EIA kit HPV GP HR; Labo Bio-medical Products, Rijswijk, The Netherlands) according to the manufacturer\'s instructions. This kit detects amplified DNA from HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. A 10 μL aliquot of GP5+/6+ amplimer from HPV positive samples by EIA was tested with the Genotyping kit HPV GP, version 2 (Labo Bio-medical Products). This kit enables genotyping of 12 hrHPV genotypes (16/18/31/33/35/39/45/51/52/56/58/59), 6 possible hrHPV types (26/53/73/82/66/68) and 5 lrHPV types (6/11/30/67/70). ([@bb0030]; [@bb0080]). Samples that were HPV positive, but were negative with the genotyping HPV GP kit were designated HPV-X.

2.5. Statistical analysis {#s0035}
-------------------------

Overall HPV prevalence between FSW and NFWS were compared with the chi-square test, genotype specific HPV prevalence with the Fisher\'s exact test. Demographical and sexual behavioural data were compared between FSW and NFWS via the chi-square test (categorical data). Fisher\'s exact test (categorical data with small groups), the independent samples *t*-test (continuous normal data) and the Mann-Whitney *U* test (continuous non-normal data). Sexual risk factors between HPV positive and HPV negative FSW were compared via the chi-square test or Fisher\'s exact test. Categorical data were described by frequencies and percentages, continuous data by means and standard deviations (SD). For all statistical analyses, SPSS version 22 (IBM Corp., Armonk, NY) were used. The significance level was set at 0.05, *p*-values \<0.1 were considered indicative for a statistical trend.

3. Results {#s0040}
==========

FSW were on average 32.2 (SD 6.6) years old, and the majority were from Colombia (68%) as opposed to the Dominican Republic (25%), while country of birth was unknown for 5 women (6.6%). Mean age of NFSW was 32.5 years (SD = 6.2, *p* = 0.75). Use of oral anticonception (OAC) was more common in the FSW (74.2%) compared to NFSW (18.1%; *p* \< 0.001). ([Table 1](#t0005){ref-type="table"}) NFSWs reported more often a history of sexual transmitted disease. Moreover, FSWs were more up to date with their visits for cervical cancer screening compared to the NFSWs: \>90% of FSW had their previous Pap smear \<3 years ago, while \>35% of NFSW never had a previous Pap smear (*p* \< 0.001).Table 1Comparison of country of birth, sexual behaviour and gynaecological medical history between FSW(*N* = 76) and NFSW(*N* = 228).Table 1FSWNFSW*p*-Valuen%n%Ethnicity\<0.001 African3754.4%20489.5% Caucasian1420.6%73.1% Asian00.0%41.8% Other1725.0%135.7% *Missing80*Oral sex0.30 No1115.3%4720.8% Yes6184.7%17979.2% Missing42Anal sex0.47 No5477.1%13081.3% Yes1622.9%3018.8% Missing668OAC\<0.001 No5981.9%5825.8% Yes1318.1%16774.2% Missing143IUD0.17 No6691.7%19285.3% Yes68.3%3314.7% Missing43Smoking0.003 No5980.8%21092.9% Yes1419.2%167.1% Missing32Alcohol0.18 No4560.8%1477.8% Yes2939.2%422.2% Missing2210Drugs0.004[a](#tf0005){ref-type="table-fn"} No6793.1%22599.6% Yes56.9%10.4% Missing42History of STD0.021 No7294.7%19184.5% Yes45.3%3515.5% Missing02Previous Pap smear\<0.001 \<3 yr.6993.2%8738.2% 3--5 yr.45.4%2511.0% \>5 yr.00.0%3214.0% Never11.4%8436.8% Missing20[^1][^2]

No significant differences was found in HPV prevalence between FSWs (25.0%) and NFSWs (29.4%) (*p* = 0.14). HPV 16 (FSW vs NFSW: 7.9% vs 3.9%, *p* = 0.22), 31(5.3% vs 3.9%, 0.74) and 18 (3.9% vs 3.1%, *p* = 0.71), were the three most common genotypes for both populations. ([Table 2](#t0010){ref-type="table"}) However, we found a significant difference in HPV-X genotypes that were untypable by reverse line blot between NFSW (5.3%) and FSW (0.0%; *p* = 0.042). HPV positive FSWs were on average younger than HPV negative FSWs (29.2 (SD 7.8) versus 33.2 (SD 6.2) years, respectively (*p* = 0.018)) ([Table 3](#t0015){ref-type="table"}). Moreover, HPV positive FSWs worked shorter in prostitution than HPV negative FSW(median of 2.5 years (range: 1.0--4.3) vs 5.0 (range: 3.0--8.0), respectively; *p* = 0.002). Lastly, there was a statistical trend for a difference in HPV prevalence in FSWs born in the Dominican Republic tended to have a higher prevalence of HPV (42.1%) compared to FSWs born in Colombia (19.2%; *p* = 0.067).Table 2Overall HPV prevalence and HPV type prevalence in FSW vs. controls (NFSW).Table 2HPV typeFSW (N = 76)controls NFSW (N = 228)*p*-Valuen%n%Any1925.0%6729.40.14600.0%31.3%0.581667.9%93.9%0.221833.9%73.1%0.713000.0%20.9%1.003145.3%93.9%0.743300.0%31.3%0.583533.9%73.1%0.713911.3%31.3%1.004511.3%62.6%0.685111.3%20.9%1.005211.3%62.6%0.685300.0%10.4%1.005600.0%52.2%0.345822.6%73.1%1.005922.6%10.4%0.166600.0%31.3%0.586722.6%20.9%0.266822.6%00.0%0.0627022.6%10.4%0.167300.0%10.4%1.00X00.0%125.3%**0.042**Table 3Risk factors associated with HPV prevalence in FSWs.Table 3HPV −HPV +*p*-Valuen%n%Age (years)**0.018** Mean (SD)33.2(6.2)29.2(7.8)Years working as FSW**0.002** Median \[range\]5.0 \[3.0--8.0\]2.5 \[1.0--4.3\]Country of birth0.067[a](#tf0010){ref-type="table-fn"} Colombia4280.8%1019.2% Dom. Rep.1157.9%842.1% Missing*41*Ethnicity0.30 African2567.6%1232.4% Caucasian1285.7%214.3% Other1482.4%317.6% Invalid*62*Country of FSW0.14[a](#tf0010){ref-type="table-fn"} Diff. countries4880.0%1220.0% Only Curacao758.3%541.7% Missing*22*Oral sex0.13[a](#tf0010){ref-type="table-fn"} No654.5%545.5% Yes4878.7%1321.3% Missing/invalid*31*Anal sex0.75[a](#tf0010){ref-type="table-fn"} No4074.1%1425.9% Yes1168.8%531.3% Missing/invalid*60*OAC0.49[a](#tf0010){ref-type="table-fn"} No4678.0%1322.0% Yes969.2%430.8% Missing/invalid*27*IUD0.62[a](#tf0010){ref-type="table-fn"} No5177.3%1522.7% Yes466.7%233.3% Missing/invalid*22*Condom0.99 No1173.3%426.7% Work and partner3373.3%1226.7% Only work571.4%228.6% Missing/invalid*81*Condom (oral)0.55 No861.5%538.5% Work and partner3376.7%1023.3% Only work675.0%225.0% Missing/invalid*102*Smoking1.00[a](#tf0010){ref-type="table-fn"} No4474.6%1525.4% Yes1071.4%428.6% Missing/invalid*540*Alcohol0.76 No3475.6%1124.4% Yes2172.4%827.6% Missing/invalid*20*Drugs0.60[a](#tf0010){ref-type="table-fn"} No5074.6%1725.4% Yes360.0%240.0% Missing/invalid*40*History of STD1.00[a](#tf0010){ref-type="table-fn"} No5475.0%1825.0% Yes375.0%125.0%Previous Pap smear0.84 \<3 yr.5173.9%1826.1% 3--5 yr.375.0%125.0% Never1100.0%00.0% Missing/don\'t known/invalid*20*[^3]

4. Discussion {#s0045}
=============

In this study we showed that HPV prevalence in NFSWs was high (29.4%). HPV prevalence in FSWs (25.0%) did not differ significantly from HPV prevalence in NFSWs. The FSWs we investigated were legal sex workers labouring in a brothel and appeared more aware of STDs. They were also more up to date with their cervical cancer screening than NFSWs from the general population. In addition we found that HPV positive FSWs were younger than HPV negative FSWs. FSWs from the Dominican Republic tended to have a higher HPV prevalence than FSWs from Colombia.

Furthermore, we will provide some possible explanations on the reason for similar HPV prevalence in FSWs and NFSWs. A low male/female ratio of 85/100 is seen in the local population ([@bb0105]). This might be an explanation for a promiscuous lifestyle mainly under the male population in a high risk region and as a result of these a high HPV prevalence. However, literatures indicates the family constellation on Curaçao and the role of men having different women has been described from the past ([@bb0080]; [@bb0010]). Other social and cultural determinants, including a high rate of illegal prostitution in the general population might be another explanation.

In 2013, Soohoo et al., published a statistical meta-analysis about a global perspective of cervical HPV infection among FSWs based on 35 papers found eligible for review. Twenty five countries in Africa, America, Eastern Mediterranean, Europe, Southeast Asia and Western Pacific were represented in this review, and in some countries multiple studies were conducted. A median overall HPV prevalence of 42.7% (range 2.3% to 100%) was reported ([@bb0100]). Differences in cervical smear collection, in HPV assays and in statistical analysis make comparison with our analysis difficult. Only one study conducted in Oviedo, Spain, used the same HPV assay as in our study and there was no significant difference in HPV prevalence. (Curaçao: 25.0%, N = 76; Oviedo Spain: 27.8%, *N* = 187; *p* = 0.64) ([@bb0035]).

During the interviews, we obtained the impression that the awareness level of primary and secondary STD prevention and former STD was notably higher in FSWs from Colombia compared to FSWs from Dominican Republic and NFSWs from Curaçao natives. Although this study was not aimed to analyse the differences in awareness level, we found a significant time difference in taking the last Pap smear for cervical screening between FSW and NFSW. Moreover, we found a higher history of STDs reported by NFSW compared to FSW. These findings confirm poor awareness of cervical cancer prevention strategies under NFSW. Furthermore, we also found a trend toward significant difference in HPV prevalence between FSWs from Dominican Republic (42,1%) and FSWs from Colombia (19.2%, *p* = 0.067). These findings are in agreement with the observation that implementation of prevention strategies, including awareness programmes in the Caribbean region is difficult ([@bb0090]; [@bb0015]).

A strength of our study is that it is the first study among the Caribbean islands to report HPV prevalence of FSWs in this high risk region for HPV and cervical cancer and also well known for sex tourism and prostitution ([@bb0080]; [@bb0095]). All anamnesis questions and cervical samples of the FSWs and NFSWs were collected by the same persons. Our study also has some limitations: a small sample size of FSW (*N* = 76) in our research population which is about the half of the legal prostitutes. These results represents only the FSWs of a legal brothel where FSWs are regularly checked for diseases while the FSWs practicing illegally and without routinely medical check-ups, are not represented by this data. HPV prevalence in this group may probably be higher. Most of these women may not have a regular medical check-up and may use less barrier contraceptives because of their social-financial status.

In conclusion, we found no significant difference in HPV prevalence between FSW and NFSW in Curaçao. FSW from Colombia have a higher awareness for STD than NFSW as the former also have less STD in the past. These data are important for health policy makers to implement cervical cancer prevention strategies.

Based on the results of our study, we advise to develop more population awareness of STDs under the general population by providing detailed information about STDs. Also, we advise the government to increase the control over illegal prostitution and to set up specialised STD centres. Moreover, we advise the ministry of health to take into account the higher attribution of non-HPV16/18 types in cervical cancer when a vaccine for prophylactic vaccination is considered.
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[^1]: Yes means current or past event. No means has never happened before.

[^2]: Fisher\'s exact test.

[^3]: Tested via the Fisher\'s exact test.
